Clinical Values of Automated Electronic Alert for Acute Kidney Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02793167|
Recruitment Status : Recruiting
First Posted : June 8, 2016
Last Update Posted : January 7, 2019
|Condition or disease||Intervention/treatment||Phase|
|Acute Kidney Injury||Device: AKI alert||Not Applicable|
A prospective, randomly controlled cohort study will be conducted agmong the patients with AKI who are detected by the use of AKI sniffer. The investigators chose to assess all inpatient serum creatinine results using a combination of "KDIGO" criteria.
The investigators randomly divided the patients into two groups:
- Usual care : patients will receive standard clinical care by the primary physicians
- AKI alert : an AKI alert will be sent to the the doctor in charge. Our team of kidney experts would give a suggestion if the the doctor in charge issue consultation applications.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2000 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Clinical Values of Automated Electronic Alert for Acute Kidney injury-a Prospective ,Randomly Controlled Cohort Study|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
No Intervention: Usual care
patients will receive standard clinical care by the doctor in charge.
Experimental: AKI alert
an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
Device: AKI alert
- Adverse events during hospitalization [ Time Frame: from start of AKI to discharge,up to 4 weeks ]cardiac shock/ need for intensive care/ cardiopulmonary resuscitation/ cardiac death/ death
- Incidence of cardiovascular disease and its occurrence time followed up for 1 years [ Time Frame: One year after discharge ]heart failure/ acute coronary syndrome/ readmission/cardiac readmission/ cardiovascular intervention or surgery
- The AKI outcome and its occurrence time followed up for 1 years [ Time Frame: One year after discharge ]AKI recovery/stop renal replacement therapy
- AKI recovery/stop renal replacement therapy [ Time Frame: from start of AKI to discharge,up to 4 weeks ]Glomerular filtration rate decreased/ new occurrence proteinuria/ original proteinuria aggravation
- Proportion of nephrology referral [ Time Frame: from start of AKI to discharge,up to 4 weeks ]
- Diagnostic rate of AKI at discharge [ Time Frame: from start of AKI to discharge,up to 4 weeks ]
- Follow-up rate after discharge [ Time Frame: One year after discharge ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02793167
|Contact: Liang Xinling, MD,PhDfirstname.lastname@example.org|
|Nephrology Dept,Guangdong General Hospital||Recruiting|
|Guangzhou, Guangdong, China|
|Contact: Liang Xinling, MD,PhD 86-13808819770 email@example.com|